All In Biotech

Drug Trial Radar · NCT06061471

To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis

A Randomized, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of AK111 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Jan 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 454 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

454

Actual

Start

Sep 22, 2023

Primary completion

Dec 11, 2024

Study completion Dec 11, 2024

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Sep 29, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind phase II clinical study to evaluate the efficacy and safety of AK111 in the treatment of subjects with moderate to severe plaque psoriasis.

Conditions

  • Psoriasis
  • Skin Diseases

Interventions

  • AK111Drug

    AK111 regimen 1-subcutaneous injection,until week 24.

  • AK111Drug

    AK111 regimen 2-subcutaneous injection,until week 24.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percentage of subjects who achieved at least 75% reduction in Psoriasis Area Severity Index (PASI)score from baseline (PASI 75) and the percentage of subjects with sPGA 0/1 at week 16.Time frame: at week 16

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, Anhui, China

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Affiliated Hospital of Chengde Medical University

    Chengde, Hebei, China

  • Nanyang First People's hospital national third class a hospital

    Nanyang, Henan, China

  • Yichang central People's hospital

    Yichang, Hubei, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The affiliated hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Dermatology hospital of Jiangxi province

    Nanchang, Jiangxi, China

  • Tianjin academy of traditional Chinese medicine affiliated hospital

    Tianjin, Tianjin Municipality, China

  • Hangzhou First People's hospital

    Hangzhou, Zhejiang, China

  • The first hospital of Jiaxing

    Jiaxing, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.